The Age
AsiaPac · 21 mins ago
NeuroScientific locks in key US FDA meeting
NeuroScientific has locked in a key meeting with the US FDA for its StemSmart technology aimed at treating refractory Crohn’s disease in a planned Phase 2 trial.
Do you trust The Age?
Sign in to rate
Discussion
?
No comments yet — be the first to start the discussion!